Analysts Offer Predictions for YMAB FY2026 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Y-mAbs Therapeutics in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will earn ($1.04) per share for the year. The consensus estimate for Y-mAbs Therapeutics' current full-year earnings is ($0.65) per share.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $20.90 million for the quarter, compared to the consensus estimate of $19.97 million.

Several other research analysts have also recently commented on YMAB. Morgan Stanley decreased their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a report on Wednesday, March 5th. Wedbush restated an "outperform" rating and set a $18.00 price target (down from $21.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, May 28th. Truist Financial cut their price objective on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Oppenheimer lowered their target price on Y-mAbs Therapeutics from $20.00 to $15.00 and set an "outperform" rating on the stock in a research note on Thursday, May 29th. Finally, Bank of America lowered shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 target price on the stock. in a research note on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $15.60.

Y-mAbs Therapeutics Stock Down 6.1%

NASDAQ:YMAB traded down $0.30 during trading hours on Tuesday, reaching $4.63. 161,686 shares of the company's stock were exchanged, compared to its average volume of 303,310. The company has a market capitalization of $209.66 million, a P/E ratio of -8.57 and a beta of 0.52. Y-mAbs Therapeutics has a 12 month low of $3.55 and a 12 month high of $16.11. The business's 50-day simple moving average is $4.42 and its two-hundred day simple moving average is $6.05.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Brooklyn Investment Group increased its position in shares of Y-mAbs Therapeutics by 4,563.8% during the 1st quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock worth $26,000 after purchasing an additional 5,796 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Y-mAbs Therapeutics during the fourth quarter worth approximately $46,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Y-mAbs Therapeutics in the 1st quarter worth $49,000. Corton Capital Inc. acquired a new position in Y-mAbs Therapeutics during the first quarter valued at approximately $55,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Y-mAbs Therapeutics in the 1st quarter valued at $56,000. 70.85% of the stock is owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.